Egg freezing surges in Canada: what PCOS patients need to know about fertility preservation options

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Egg freezing in Canada grew from 217 retrieval cycles in 2013 to 2,663 in 2025, a twelvefold increase documented by the Canadian Fertility and Andrology Society (CFAS) in its 2026 annual report. For patients with polycystic ovary syndrome (PCOS), a hormonal condition affecting roughly 8 to 13 percent of Canadian women of reproductive age, that surge is both an opportunity and a reason to proceed carefully with specialist guidance.

For a hormone-care patient in Canada, the practical picture is this: elective egg freezing is not covered by any provincial health plan, including OHIP in Ontario, RAMQ in Quebec, MSP in British Columbia, or AHCIP in Alberta. One cycle typically costs $8,000 to $16,000 CAD all-in, depending on medication doses and clinic fees. Some employer benefits plans cover part of the cost, but coverage is inconsistent and often capped. Patients with PCOS face an additional clinical wrinkle: their ovaries tend to respond more strongly to the hormone injections used in stimulation, which raises the risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication that requires monitoring by a reproductive endocrinologist.

What this means in Canada

Health Canada has not issued a specific regulatory position on elective egg freezing as a standalone procedure. The process involves controlled ovarian stimulation using gonadotropins (sold in Canada under brand names including Gonal-F and Puregon), followed by egg retrieval and vitrification, a rapid-freeze technique that has largely replaced slow-freeze methods since the early 2010s. These medications are Health Canada-approved for ovarian stimulation in assisted reproduction, but their use in elective freezing cycles falls under clinical discretion rather than a dedicated regulatory framework.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has published guidance on fertility preservation in the context of medical necessity, such as before cancer treatment, but has not issued a standalone position statement on elective social egg freezing as of October 2026. CFAS, the national body that tracks assisted reproduction data, supports access to the procedure and has called for greater provincial funding equity.

Provincially, Ontario funds one IVF cycle for patients who meet specific criteria under OHIP, but elective egg freezing is excluded. Quebec's RAMQ previously covered IVF cycles but scaled back public funding in 2015; elective egg freezing remains uncovered. British Columbia and Alberta offer no public funding for either IVF or elective egg freezing. Some patients access partial reimbursement through workplace benefits or health spending accounts, but this varies widely by employer.

Canadian fertility clinics offering egg freezing include Twig Fertility (Toronto), Olive Fertility Centre (Vancouver), Create Fertility (Toronto), and Mount Sinai Fertility (Toronto), among others. Telehealth platforms such as Cleo, a Canadian women's-health platform, and Science and Humans (scienceandhumans.com) offer hormonal health consultations but do not perform egg retrievals. US-based platforms like Midi Health and Hone Health do not serve Canadian patients.

Why this matters

The CFAS data show that stored egg counts rose from roughly 775 in 2013 to more than 22,000 in 2025. That volume reflects a real shift in how Canadians are thinking about reproductive timelines. Statistics Canada data show the average age of mothers at delivery climbed from 26.7 in 1976 to 31.6 in 2022. Egg quality and quantity decline steadily from the early 30s, with a faster drop after age 35, which is why reproductive specialists consistently advise that earlier retrieval produces better outcomes.

For patients with PCOS specifically, the timing question is complicated. PCOS is associated with a higher antral follicle count, meaning more eggs are typically available for retrieval. That sounds advantageous, and in some ways it is: patients with PCOS often retrieve more eggs per cycle than the general population. But the same hormonal profile that produces more follicles also increases OHSS risk during stimulation. A 2024 systematic review published in Fertility and Sterility found that OHSS rates are meaningfully higher in PCOS patients undergoing ovarian stimulation, and that careful dose adjustment and monitoring protocols reduce but do not eliminate that risk. Clinics now commonly use a GnRH agonist trigger instead of an hCG trigger in PCOS patients to lower OHSS incidence, but this requires a freeze-all approach, meaning no fresh embryo transfer in the same cycle.

A separate consideration: a 2024 systematic review and meta-analysis cited by CBC News found that only about 11 percent of people who froze their eggs had returned to use them. That figure will likely rise as the cohort of patients who froze eggs in their 30s reaches their 40s, but it is a real data point for anyone weighing the cost-benefit calculation.

What Canadian patients should know

A consultation with a reproductive endocrinologist is the starting point. Most Canadian fertility clinics offer an initial consult that includes bloodwork (AMH, FSH, antral follicle count) to estimate ovarian reserve. For PCOS patients, this baseline assessment is especially informative because it helps predict stimulation response and flag OHSS risk before any medication is prescribed.

Cost planning matters early. One cycle with medication and one year of storage runs roughly $11,000 to $16,000 CAD at most Canadian clinics, according to Dr. Rhonda Zwingerman of Twig Fertility, speaking to CBC News. Some patients do two or three cycles to bank more eggs, which multiplies costs. Annual storage fees typically run $500 to $800 CAD per year after the first year.

Geography is a real barrier. Egg retrieval requires an in-clinic procedure and multiple monitoring appointments during the stimulation phase, typically over 10 to 14 days. Patients outside major urban centres face travel costs on top of procedure costs. Dr. Zwingerman told CBC News she would like to see outreach facilities built beyond city centres, but that infrastructure does not yet exist at scale.

Workplace benefits are worth checking. Some employers, particularly in tech and finance, have added fertility benefits that cover part of egg freezing costs. The coverage landscape is uneven, but it is worth reviewing your group benefits plan or asking HR before assuming the full cost is out of pocket.

For PCOS patients specifically: tell your clinic about your diagnosis before stimulation begins. Dose protocols differ from standard stimulation, and your clinic should have a clear OHSS prevention plan in place.

Limitations and open questions

The 11 percent return-to-use figure is low, and researchers do not yet have long-term Canadian data on live birth rates from eggs frozen electively (as opposed to eggs frozen before cancer treatment). The SOGC has not issued a position statement on elective egg freezing, so there is no national clinical guideline specific to this use case. Health Canada has not established a regulatory pathway specific to elective vitrification, meaning oversight falls to provincial colleges of physicians and individual clinic accreditation through CFAS.

For PCOS patients, there is also limited published data on long-term outcomes from eggs retrieved under PCOS-specific protocols. The Endocrine Society's 2023 PCOS clinical practice guideline addresses fertility treatment broadly but does not provide specific recommendations on elective egg freezing in PCOS. That gap means clinical decisions rest heavily on individual specialist judgment rather than standardized national guidance.

Finally, the cost barrier is not trivial. CFAS president Dr. Mohamed Bedaiwy told CBC News plainly: those who can afford it can do it, and those who cannot are excluded. Until provincial coverage expands or a national pharmacare framework addresses fertility medications, access will remain unequal across income levels and geography.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.